Videnova, Vilma

Preferred name
Videnova, Vilma
Official Name
Videnova, Vilma
Main Affiliation
Email
vilma.videnova@medf.ukim.edu.mk

Settings

Now showing 1 - 3 of 3
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Comorbidity in hospitalized patients with schizophrenia
    (Elsevier, 2018-03)
    ;
    ;
    Introduction.– There is an insufficient awareness of comorbidity in schizophrenia on the part of patients, caregivers, health care providers, and researchers. Comorbidity has often been underrecognized and underdiagnosed in psychiatric patients, especially among those with schizophrenia. Objective.– The aim of this study is to analyze comorbidity in hospitalized patients with schizophrenia. Methods.– Medical charts of 96 inpatients with schizophrenia (42 male and 54 female, aged 19-65) were retrospectively analysed in terms of comorbidity. Results.– Comorbid substance abuse was found in 17 patients, 7 patients had personality disorders, while 34 had anxiety disorders. Conclusions.– Comorbid substance abuse leads to poorer medication compliance, higher rates of rehospitalization, poorer adjustment and treatment response in schizophrenia patients. Increased likelihood of violent behaviour and greater use of emergency services are also associated with substance abuse in schizophrenia. Comorbidity has negative impact on treatment outcome in schizophrenia patients which affects the prospects of discharge in this patients and their quality of life Disclosure of interest.– The authors have not supplied their declaration of competing interest.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Pharmacotherapy of agitation in dementia
    (Macedonian Psychiatric Association, 2019)
    ;
    ;
    ;
    Snezana Pejkovska-Dimovska
    Although we tend to focus on the cognitive issues ,the behavior of individuals with dementia is often the main problem that leads to institutionalization. Clinical guidelines recommend nonpharmacological approaches as the first choice in the treatment of behavioral and psychological symptoms [1]. Acetylcholinesterase inhibitors (AChEI) are the first-line pharmacological option ,but challenging risky behaviors may persist despite their use. Antipsychotics are indicated in such cases, but there is very limited evidence to support the efficacy and safety of these medications for managing agitation in dementia[2]. Antipsychotics are prescribed most often for this indication and, at the same time, are related to the highest risk of adverse effects and increased mortality. Compared with the common population, lower doses should be used and titrated gradually. When choosing the medication, pharmacokinetic and pharmacodynamic interaction with AChEI and memantine used by majority of patients with dementia should be considered [3][4].
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Globulin levels in acute and chronic psychotic patients
    (Morressier, 2019-07-11)
    ;
    ;
    ;
    Pejkovska Dimovska, S
    Background : A number of studies suggest that psychiatric symptoms, particularly at early stages of the illness, may be alleviated by targeting affected peripheral pathways such as the immune/inflammatory system. [1] [2] Objective: To analyze globulin levels in acute and chronic psychotic patients. Materials and methods: To 141 hospitalized patients (92 male and 49 female, 94 diagnosed with acute psychotic disorder (F20.0,F21,F23,F25), 47 diagnosed with chronic psychotic disorder (F20.5) according to ICD-10 criteria in Psychiatric Hospital Skopje, Macedonia, globulin test was performed [3]. All patients were aged 18-62 years (mean age, 40 years). Reference range for calculated globulin (CG) was from 27 to 35g/L. Comparative data analysis was applied. Results: From 94 acute psychotic patients (61 male and 33 female), 60 patients (37 male and 23 female) or 63,8% had low CG. In chronic psychotic group, from 47 patients (31 male and 16 female), 18 patients ( 11 male and 7 female) or 38,3% had high CG There were no patients with high CG in acute psychotic group and no patients with low CG in chronic psychotic group. Conclusions: Some findings suggest that innate immunity may be depressed early in the course of a psychotic illness and elevated later in the schizophrenia disease process [4]. While there have been significant advances in our understanding of basic neuroscience over the years, this has not translated into psychiatric clinical practice.